查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1670871

2025年前列腺癌診斷全球市場報告

Prostate Cancer Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年前列腺癌診斷的市場規模將快速成長。預計到 2029 年將成長至 81.7 億美元，複合年成長率為 12.9%。預測期內的成長可歸因於人工智慧 (AI) 的整合、癌症篩檢中遠端醫療的成長、基因組分析的進步、以患者為中心的方法以及用於診斷的多參數 MRI 等。預測期內的關鍵趨勢包括液態切片技術、生物標記檢測技術進步、臨床研究和開發、數位病理整合以及多重生物標記檢測的出現。

由於前列腺癌盛行率的不斷上升，前列腺癌診斷市場預計將會成長。前列腺癌是一種影響男性和女性生殖器官中前列腺的疾病，需要透過各種測試進行早期診斷，包括前列腺特異性抗原 (PSA) 測試和先進的影像技術。 2023年1月，美國癌症協會（ACS）報告稱，預計當年前列腺癌新患者將達288,300例，並有34,700人死於該疾病。因此，攝護腺癌盛行率的上升預計將推動攝護腺癌診斷市場的擴張。

前列腺癌診斷市場的成長受到醫療保健支出增加的推動。醫療保健支出是指特定地區、國家或組織分配給醫療保健部門的總財政資源。這筆支出將支持前列腺癌診斷資源的分配和使用，以促進早期發現、準確分期和及時干預，旨在改善前列腺癌患者的治療效果、生存率和整體護理品質。例如，2023年5月，英國政府部門國家統計局報告稱，2022年至2023年英國醫療保健支出增加了5.6%，而2022年的增幅為0.9%。 2023年英國醫療保健支出將達到約3,176.3億美元（2,920億英鎊）。因此，醫療保健支出的增加正在推動前列腺癌診斷市場的未來成長。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、新冠疫情、經濟復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球前列腺癌診斷PESTEL分析（政治、社會、技術、環境、法律因素、促進因素、限制因素）
  • 最終用途產業分析
  • 全球前列腺癌診斷市場：成長率分析
  • 全球前列腺癌診斷市場表現：規模與成長，2019-2024
  • 全球前列腺癌診斷市場預測：規模與成長，2024-2029 年，2034 年
  • 全球前列腺癌診斷總目標市場（TAM）

第6章市場區隔

  • 全球前列腺癌診斷市場（依產品、績效及預測）：2019-2024 年、2024-2029 年、2034 年
  • 裝置
  • 試劑和耗材
  • 配件
  • 全球前列腺癌診斷市場依檢測類型、效能及預測，2019-2024 年、2024-2029 年、2034 年
  • 初步檢查
  • 確認檢查
  • 全球前列腺癌診斷市場：按前列腺癌類型、表現和預測，2019-2024 年、2024-2029 年、2034 年
  • 鱗狀細胞癌
  • 小細胞癌
  • 移行細胞癌
  • 攝護腺腺癌
  • 導管腺癌
  • 小細胞前列腺癌
  • 腺泡腺癌
  • 全球前列腺癌診斷市場（以Peer Group）、績效及預測（2019-2024 年、2024-2029 年及 2034 年）
  • 對於成年人
  • 小兒科
  • 老年病學
  • 全球前列腺癌診斷市場：按最終用戶、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 獨立診斷實驗室
  • 癌症研究所
  • 其他最終用戶
  • 全球前列腺癌診斷市場細分（按設備、產品、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • 切片檢查器械
  • 影像設備
  • 直腸指診儀
  • 全球前列腺癌診斷市場按試劑和耗材、產品、性能和預測進行細分，2019-2024 年、2024-2029 年、2034 年
  • 診斷檢測試劑套件
  • 染色試劑
  • 樣本收集材料
  • 全球前列腺癌診斷市場細分（按配件、產品、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • 切片檢查指南
  • 標本處理配件
  • 校準和維護工具

第7章 區域和國家分析

  • 全球前列腺癌診斷市場各地區表現及預測（2019-2024 年、2024-2029 年及 2034 年）
  • 全球前列腺癌診斷市場：按國家、績效和預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章競爭格局與公司概況

  • 攝護腺癌診斷市場：競爭格局
  • 前列腺癌診斷市場：公司簡介
    • F. Hoffman-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

  • Becton Dickinson and Company
  • Agilent Technologies Inc.
  • Hologic Inc
  • Biomerieux SA
  • Beckman Coulter Inc.
  • Qiagen NV
  • EXACT Sciences Corporation
  • Diasorin SPA
  • OPKO Health Inc.
  • Myriad Genetics Inc.
  • Cepheid Inc
  • NeoGenomics Laboratories Inc.
  • Guardant Health Inc
  • GRAIL Inc
  • Fujirebio Diagnostics Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

  • 2029年前列腺癌診斷市場：提供新機會的國家
  • 2029年前列腺癌診斷市場：細分領域帶來新機會
  • 2029年前列腺癌診斷市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第36章 附錄

簡介目錄
Product Code: r25241

Prostate cancer diagnostics involve the process of determining and confirming the presence of prostate cancer through diagnostic testing and medical evaluations. The primary aim is to assess the status and severity of the illness, guiding treatment choices. This diagnostic approach is commonly applied in the treatment of prostatic adenocarcinoma, transitional cell carcinomas, and neuroendocrine tumors.

The main products in prostate cancer diagnostics include instruments, reagents and consumables, and accessories. Accessories encompass items in the kit that may not be strictly necessary but can enhance effectiveness, such as a prostate-specific antigen (PSA) test kit, biopsy needle, and ultrasound gel, all utilized in the diagnosis of prostate cancer. Various test types, including preliminary and confirmatory tests, diagnose different types of prostate cancers, such as squamous cell cancer, small cell carcinoma, transitional cell cancer, prostatic adenocarcinoma, ductal adenocarcinoma, small cell prostate cancer, and acinar adenocarcinoma. These diagnostic tests are applicable to various age groups, including adults, pediatric, and geriatric populations, and are performed by different end users, including hospitals, independent diagnostic laboratories, cancer research institutes, and others.

The prostate cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides prostate cancer diagnostics market statistics, including prostate cancer diagnostics industry global market size, regional shares, competitors with a prostate cancer diagnostics market share, detailed prostate cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer diagnostics industry. This prostate cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate cancer diagnostics market size has grown rapidly in recent years. It will grow from $4.43 billion in 2024 to $5.03 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to the increasing aging population, advancements in medical imaging, rising awareness and screening programs, public health initiatives, and improved biopsy techniques

The prostate cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $8.17 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to the integration of artificial intelligence (AI), growth of telemedicine in cancer screening, advancements in genomic profiling, patient-centric approaches, and multiparametric MRI for diagnosis. Major trends in the forecast period include liquid biopsy technologies, technological advances in biomarker detection, clinical research and development, digital pathology integration, emergence of multiplex biomarker assays.

The prostate cancer diagnostics market is anticipated to experience growth, driven by the increasing prevalence of prostate cancer. This condition, affecting the prostate gland in the male and female reproductive systems, necessitates early diagnosis through various tests, including prostate-specific antigen (PSA) testing and advanced imaging techniques. In January 2023, the American Cancer Society (ACS) reported an estimated 288,300 new cases of prostate cancer and 34,700 deaths attributed to the disease for the same year. Consequently, the rising prevalence of prostate cancer is expected to fuel the expansion of the prostate cancer diagnostics market.

The growth of the prostate cancer diagnosis market is being driven by an increase in healthcare spending. Healthcare spending refers to the total financial resources allocated to the healthcare sector within a specific region, country, or organization. This spending supports the allocation and use of resources for prostate cancer diagnosis, facilitating early detection, accurate staging, and timely intervention, all aimed at improving patient outcomes, survival rates, and the overall quality of care for those affected by prostate cancer. For example, in May 2023, a report from the Office for National Statistics, a UK-based government department, indicated that healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared to a growth of 0.9% in 2022. The UK healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. Thus, the increase in healthcare spending is propelling the growth of the prostate cancer diagnosis market in the future.

Technological innovations represent a prominent trend in the prostate cancer diagnostics market, with major companies introducing advanced AI-powered tools for diagnosis. In March 2023, Qritive, a Singapore-based company, launched QAi Prostate-an AI-powered prostate cancer diagnosis tool designed for pathologists. This tool employs sophisticated machine learning algorithms to identify prostatic adenocarcinoma regions and analyze whole slide images of prostate core needle biopsies. The innovative tool facilitates accurate and swift diagnoses, reducing treatment time.

Strategic partnerships are a key approach adopted by major companies in the prostate cancer diagnostics market to advance cancer precision medicine. In March 2022, Lantheus Holdings Inc., a US-based diagnostic and imaging products company, partnered with Novartis AG, a Switzerland-based pharmaceutical company, to utilize Lantheus' prostate-specific membrane antigen (PSMA) imaging agent, PYLARIFY, in clinical trials for Pluvicto. This collaboration aims to enhance the diagnosis of patients with prostate cancer for improved treatment outcomes.

In August 2022, MDxHealth SA, a US-based precision diagnostics company, acquired Exact Sciences Corporation to bolster its leadership in the precision diagnostics urology market. This acquisition expanded MDxHealth's prostate diagnostics business with the inclusion of the Oncotype DX GPS (Genomic Prostate Score) test. Exact Sciences Corporation, a US-based cancer screening and diagnostic tests company, brought valuable assets, including prostate pipelines software supporting patients throughout their cancer diagnosis and treatment.

Major companies operating in the prostate cancer diagnostics market include F. Hoffman-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Becton Dickinson and Company, Agilent Technologies Inc., Hologic Inc, Biomerieux SA, Beckman Coulter Inc., Qiagen N.V., EXACT Sciences Corporation, Diasorin S.P.A., OPKO Health Inc., Myriad Genetics Inc., Cepheid Inc, NeoGenomics Laboratories Inc., Guardant Health Inc, GRAIL Inc, Fujirebio Diagnostics Inc., Ambry Genetics Corporation, MDxHealth SA, Biocept Inc., Blue Earth Therapeutics Ltd, Exosome Diagnostics Inc., Dana-Farber Cancer Institute, Cellanyx Diagnostics Inc., A3P Biomedical AB

North America was the largest region in the prostate cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the prostate cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prostate cancer diagnostics market consists of revenues earned by entities by providing transrectal ultrasound, magnetic resonance imaging (MRI), and computerized tomography (CT) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The prostate cancer diagnostics market also includes sales of products such as tumor biopsies, and test kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prostate cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Products: Instruments; Reagents And Consumables; Accessories
  • 2) By Test Type: Preliminary Tests; Confirmatory Tests
  • 3) By Prostate Cancer: Squamous Cell Cancer; Small Cell Carcinoma; Transitional Cell Cancer; Prostatic Adenocarcinoma; Ductal Adenocarcinoma; Small Cell Prostate Cancer; Acinar Adenocarcinoma
  • 4) By Peer Groups: Adult; Pediatric; Geriatrics
  • 5) By End User: Hospitals; Independent Diagnostic Laboratories; Cancer Research Institutes; Other End-Users
  • Subsegments:
  • 1) By Instruments: Biopsy Instruments; Imaging Devices; Digital Rectal Examination Tools
  • 2) By Reagents And Consumables: Diagnostic Assay Kits; Staining Reagents; Sample Collection Materials
  • 3) By Accessories: Biopsy Guides; Specimen Handling Accessories; Calibration And Maintenance Tools
  • Companies Mentioned: F. Hoffman-La Roche AG; Bayer AG; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.; Siemens Healthineers AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Prostate Cancer Diagnostics Market Characteristics

3. Prostate Cancer Diagnostics Market Trends And Strategies

4. Prostate Cancer Diagnostics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Prostate Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Prostate Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Prostate Cancer Diagnostics Market Growth Rate Analysis
  • 5.4. Global Prostate Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Prostate Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Prostate Cancer Diagnostics Total Addressable Market (TAM)

6. Prostate Cancer Diagnostics Market Segmentation

  • 6.1. Global Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Instruments
  • Reagents And Consumables
  • Accessories
  • 6.2. Global Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Preliminary Tests
  • Confirmatory Tests
  • 6.3. Global Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Squamous Cell Cancer
  • Small Cell Carcinoma
  • Transitional Cell Cancer
  • Prostatic Adenocarcinoma
  • Ductal Adenocarcinoma
  • Small Cell Prostate Cancer
  • Acinar Adenocarcinoma
  • 6.4. Global Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Adult
  • Pediatric
  • Geriatrics
  • 6.5. Global Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Independent Diagnostic Laboratories
  • Cancer Research Institutes
  • Other End-Users
  • 6.6. Global Prostate Cancer Diagnostics Market, Sub-Segmentation Of Instruments, By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biopsy Instruments
  • Imaging Devices
  • Digital Rectal Examination Tools
  • 6.7. Global Prostate Cancer Diagnostics Market, Sub-Segmentation Of Reagents And Consumables, By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Diagnostic Assay Kits
  • Staining Reagents
  • Sample Collection Materials
  • 6.8. Global Prostate Cancer Diagnostics Market, Sub-Segmentation Of Accessories, By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biopsy Guides
  • Specimen Handling Accessories
  • Calibration And Maintenance Tools

7. Prostate Cancer Diagnostics Market Regional And Country Analysis

  • 7.1. Global Prostate Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Prostate Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Prostate Cancer Diagnostics Market

  • 8.1. Asia-Pacific Prostate Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Prostate Cancer Diagnostics Market

  • 9.1. China Prostate Cancer Diagnostics Market Overview
  • 9.2. China Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Prostate Cancer Diagnostics Market

  • 10.1. India Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Prostate Cancer Diagnostics Market

  • 11.1. Japan Prostate Cancer Diagnostics Market Overview
  • 11.2. Japan Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Prostate Cancer Diagnostics Market

  • 12.1. Australia Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Prostate Cancer Diagnostics Market

  • 13.1. Indonesia Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Prostate Cancer Diagnostics Market

  • 14.1. South Korea Prostate Cancer Diagnostics Market Overview
  • 14.2. South Korea Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Prostate Cancer Diagnostics Market

  • 15.1. Western Europe Prostate Cancer Diagnostics Market Overview
  • 15.2. Western Europe Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Prostate Cancer Diagnostics Market

  • 16.1. UK Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Prostate Cancer Diagnostics Market

  • 17.1. Germany Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Prostate Cancer Diagnostics Market

  • 18.1. France Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Prostate Cancer Diagnostics Market

  • 19.1. Italy Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Prostate Cancer Diagnostics Market

  • 20.1. Spain Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Prostate Cancer Diagnostics Market

  • 21.1. Eastern Europe Prostate Cancer Diagnostics Market Overview
  • 21.2. Eastern Europe Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Prostate Cancer Diagnostics Market

  • 22.1. Russia Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Prostate Cancer Diagnostics Market

  • 23.1. North America Prostate Cancer Diagnostics Market Overview
  • 23.2. North America Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Prostate Cancer Diagnostics Market

  • 24.1. USA Prostate Cancer Diagnostics Market Overview
  • 24.2. USA Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Prostate Cancer Diagnostics Market

  • 25.1. Canada Prostate Cancer Diagnostics Market Overview
  • 25.2. Canada Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Prostate Cancer Diagnostics Market

  • 26.1. South America Prostate Cancer Diagnostics Market Overview
  • 26.2. South America Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Prostate Cancer Diagnostics Market

  • 27.1. Brazil Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Prostate Cancer Diagnostics Market

  • 28.1. Middle East Prostate Cancer Diagnostics Market Overview
  • 28.2. Middle East Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Prostate Cancer Diagnostics Market

  • 29.1. Africa Prostate Cancer Diagnostics Market Overview
  • 29.2. Africa Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Prostate Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Prostate Cancer Diagnostics Market Competitive Landscape
  • 30.2. Prostate Cancer Diagnostics Market Company Profiles
    • 30.2.1. F. Hoffman-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

31. Prostate Cancer Diagnostics Market Other Major And Innovative Companies

  • 31.1. Becton Dickinson and Company
  • 31.2. Agilent Technologies Inc.
  • 31.3. Hologic Inc
  • 31.4. Biomerieux SA
  • 31.5. Beckman Coulter Inc.
  • 31.6. Qiagen N.V.
  • 31.7. EXACT Sciences Corporation
  • 31.8. Diasorin S.P.A.
  • 31.9. OPKO Health Inc.
  • 31.10. Myriad Genetics Inc.
  • 31.11. Cepheid Inc
  • 31.12. NeoGenomics Laboratories Inc.
  • 31.13. Guardant Health Inc
  • 31.14. GRAIL Inc
  • 31.15. Fujirebio Diagnostics Inc.

32. Global Prostate Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prostate Cancer Diagnostics Market

34. Recent Developments In The Prostate Cancer Diagnostics Market

35. Prostate Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 35.1 Prostate Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Prostate Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Prostate Cancer Diagnostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer